Vertex Pharmaceuticals Net Income vs. EBITDA
VRTX Stock | USD 464.56 2.51 0.54% |
Net Income | First Reported 1991-06-30 | Previous Quarter -3.6 B | Current Value 1 B | Quarterly Volatility 461.7 M |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 1.09 | 0.8721 |
|
|
For Vertex Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Vertex Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Vertex Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Vertex Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Vertex Pharmaceuticals over time as well as its relative position and ranking within its peers.
Vertex |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vertex Pharmaceuticals. If investors know Vertex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vertex Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.01 | Earnings Share (1.90) | Revenue Per Share 41.185 | Quarterly Revenue Growth 0.116 | Return On Assets 0.1205 |
The market value of Vertex Pharmaceuticals is measured differently than its book value, which is the value of Vertex that is recorded on the company's balance sheet. Investors also form their own opinion of Vertex Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Vertex Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vertex Pharmaceuticals' market value can be influenced by many factors that don't directly affect Vertex Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vertex Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vertex Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vertex Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Vertex Pharmaceuticals EBITDA vs. Net Income Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Vertex Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Vertex Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Vertex Pharmaceuticals is rated second in net income category among its peers. It is rated first in ebitda category among its peers totaling about 1.27 of EBITDA per Net Income. At this time, Vertex Pharmaceuticals' Net Income is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Vertex Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Vertex Pharmaceuticals' Earnings Breakdown by Geography
Vertex EBITDA vs. Net Income
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Vertex Pharmaceuticals |
| = | 3.62 B |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Vertex Pharmaceuticals |
| = | 4.61 B |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Vertex EBITDA Comparison
Vertex Pharmaceuticals is currently under evaluation in ebitda category among its peers.
Vertex Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Vertex Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Vertex Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Vertex Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Vertex Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last Reported | Projected for Next Year | ||
Accumulated Other Comprehensive Income | -14.3 M | -13.6 M | |
Operating Income | 4.3 B | 4.5 B | |
Net Income | 3.6 B | 3.8 B | |
Income Tax Expense | 760.2 M | 798.2 M | |
Income Before Tax | 4.4 B | 4.6 B | |
Total Other Income Expense Net | 72.3 M | 75.9 M | |
Net Income From Continuing Ops | 3.6 B | 3.8 B | |
Non Operating Income Net Other | -23.2 M | -22.1 M | |
Net Income Applicable To Common Shares | 3.8 B | 4 B | |
Interest Income | 614.7 M | 645.4 M | |
Net Interest Income | 570.6 M | 599.1 M | |
Change To Netincome | 512.4 M | 437.4 M | |
Net Income Per Share | 14.05 | 14.75 | |
Income Quality | 0.98 | 0.71 | |
Net Income Per E B T | 0.83 | 0.73 |
Vertex Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Vertex Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Vertex Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Vertex Pharmaceuticals' important profitability drivers and their relationship over time.
Use Vertex Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Vertex Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vertex Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Vertex Pharmaceuticals Pair Trading
Vertex Pharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to Vertex Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Vertex Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Vertex Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Vertex Pharmaceuticals to buy it.
The correlation of Vertex Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Vertex Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Vertex Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Vertex Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Vertex Pharmaceuticals position
In addition to having Vertex Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Emerging Markets Funds Thematic Idea Now
Emerging Markets Funds
Fund or Etfs that invest in markets of developing countries. The Emerging Markets Funds theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Emerging Markets Funds Theme or any other thematic opportunities.
View All Next | Launch |
Additional Tools for Vertex Stock Analysis
When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.